Development of a Japanese Version of the Daily Record of Severity of Problems for Diagnosing Premenstrual Syndrome by Ikeda, Yumie et al.
Title Development of a Japanese Version of the Daily Record ofSeverity of Problems for Diagnosing Premenstrual Syndrome
Author(s)
Ikeda, Yumie; Egawa, Miho; Hiyoshi, Kazuko; Ueno, Tsukasa;
Ueda, Keita; Becker, Carl B.; Takahashi, Yoshimitsu;
Nakayama, Takeo; Mandai, Masaki




© Yumie Ikeda et al. 2020; Published by Mary Ann Liebert,
Inc.; This Open Access article is distributed under the terms of
the Creative Commons License (
http://creativecommons.org/licenses/by/4.0), which permits
unrestricted use, distribution, and reproduction in any medium,




ORIGINAL ARTICLE Open Access
Development of a Japanese Version of the Daily
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Abstract
Background: Premenstrual syndrome (PMS) causes physical and mental symptoms in women during the luteal
phase of the menstruation cycle. To confirm the relationship between symptoms and the menstruation cycle,
daily symptom records are essential for diagnosing PMS. The daily record of severity of problems (DRSP) is cur-
rently the most validated tool for tracking symptoms to confirm and scale the severity of PMS, but there has been
no validated Japanese version of this instrument. We developed a Japanese version of the DRSP and assessed its
psychometric properties.
Methods: A Japanese version of the DRSP was developed following the translation guidelines of the latest
Patient-Reported Outcomes Consortium. We conducted a computational psychometric study among 119
women, all of whom completed the Japanese version of the DRSP, the Center for Epidemiologic Studies
Depression Scale (CES-D), the Premenstrual Dysphoric Disorder (PMDD) scale, and a Numerical Rating
Scale (NRS) for general health status. Each was filled out twice, 2 weeks apart, so that one set was completed
in the luteal phase.
Results: The Japanese version of the DRSP was developed with translation and cultural adaptation. The internal
consistency coefficient for the total score was 0.93. The DRSP in the luteal phase correlated highly with the CES-D,
PMDD scale, and NRS for general health status.
Conclusions: Our Japanese version of the DRSP, developed as a PMS/PMDD diagnostic tool, was shown to pro-
vide substantial validity and reliability to rate premenstrual symptoms for Japanese women.
Keywords: Japanese; daily record of severity of problems; premenstrual syndrome
Introduction
Premenstrual syndrome (PMS) causes physical and
mental symptoms in women during the luteal phase
of the menstruation cycle. Approximately 70%–90%
of menstruating women experience some premen-
strual symptoms,1 and 20%–40% experience troublesome
PMS. Between 1% and 8% of women have premenstrual
dysphoric disorder (PMDD), the most severe form of
PMS, which interferes with daily work, school, social
life, and relationships.1–3
The American College of Obstetrics and Gynecology
(ACOG) has defined diagnostic criteria for PMS that re-
quire patients keep prospective daily records to deter-
mine whether symptoms worsen cyclically, but it has
not specified a recording tool.3 Prospective recording
tools include the daily record of severity of problems
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(DRSP), the premenstrual records of impact and severity
of menstruation (PRISM), the calendar of premenstrual
experiences (COPE), and the daily symptom report
(DSR)4; recently, the British Royal College of Obstetrics
and Gynecology (RCOG) recommended using the DRSP,
currently the most commonly recommended tool for
tracking premenstrual symptoms.5 The DRSP was cre-
ated in 1997 based on the diagnostic criteria for PMDD
of the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV).6 The DSM-5, re-
leased in 2013, was essentially the same criteria for
diagnosis.7 Therefore, the DRSP is still most widely
recommended. The utility and validity of the English
version of the DRSP in measuring the severity and
fluctuations of PMS have been established.8
Although some retrospective studies have estimated
that PMS affects almost one-fifth of Japanese women,9
Japan lacks any validated diagnostic tool for PMS.
Many epidemiological studies of PMS in Japan have
used retrospective questionnaires9–13 that have shown
little correspondence with diagnoses based on pro-
spective recording.14,15 Moreover, no Japanese scale
measured the severity of PMS. Just as we were con-
ducting our own work on this field, one Japanese ver-
sion of the DRSP has been reported,16 substantially
advancing the possibilities for PMS research in Japan.
However, the DSRP includes a range of psychological el-
ements demanding great care and cultural sensitivity in
any translation. Only in 2018, the Patient-Reported Out-
comes (PRO) Consortium (formed by the Critical Path
Institute [C-Path] in cooperation with the U.S. FDA
Center for Drug Evaluation and Research and the phar-
maceutical industry) updated their guide to enable differ-
ent translation companies to share standard procedures
for translation and cultural adaptation (TCA).17 These
new guidelines require 12 carefully defined steps to
achieve an unprecedented level of precision in medical
translation, including reconciliation of plural parallel
fore translations and back translations, cognitive inter-
viewing, and incorporation of interview feedback into
the final translation. The DSRP-J that has just appeared
is a welcome new focus of attention on this field, but it
fails to explicitly incorporate comparison and reconcil-
iation of plural translations, much less interviews about
their psychological impact on the types of respondents
to be studied. Convinced of the importance of not only
medically precise but also culturally and psychologically
sensitive wording, we based our new translation on
PRO Consortium guidelines, and statistically confirmed
its validity and reliability as a diagnostic scale for PMS.
Methods
Daily record of severity of problems
The DRSP comprises 21 items describing premenstrual
symptoms and 3 items concerning the dysfunction in
daily life caused by these symptoms.18 Throughout the
menstrual cycle, all 24 items are ranked daily from 1
(not at all) to 6 (extreme). The DRSP contains three
clinically determined subscales: depressive symptoms
(felt depressed, felt hopeless, felt worthless or guilty,
slept more, trouble sleeping, and felt overwhelmed);
physical symptoms (breast tenderness, bloating, head-
ache, and joint or muscle pain); and anger/irritability
(anger/irritability and personal conflicts). A total DRSP
score of <50 at the onset of menstruation indicates the
absence of PMS.18
TCA of the DRSP
In 2005, principles of good practice for the TCA of
PROmeasures was published by the International Soci-
ety for Pharmacoeconomics and Outcomes Research
(ISPOR).19 In 2018, the PRO Consortium (formed by
the Critical Path Institute [C-Path] in cooperation with
the U.S. FDA Center for Drug Evaluation and Research
and the pharmaceutical industry) updated this guide to
enable different translation companies to share standard
procedures for TCA.17 The new guide did not change the
principles of TCA, but it details how to perform each step
and how to adapt the TCA process to different situations
worldwide.17
The Japanese version of the DRSP was developed
based on the 2018 PRO Consortium consensus guide
for translating and culturally adapting PRO into other
languages, which constitutes a 12-step process (Supple-
mentary Appendix Table SA1). We followed the 12
steps to develop the Japanese version of the DRSP, in-
cluding conducting cognitive interviews (step 9) of 8
PMDD outpatients at Kyoto University Hospital.
Participants
Our research was intended to examine the reliability and
validity of the DRSP for measuring PMS in Japanese. We
recruited study participants from October to December
2018 from students at the Public School of Kyoto Univer-
sity and Doshisha Women’s College of Liberal Arts, and
from staff members at Kyoto University Hospital. The
convenience sample included 119 women (median age,
range= 31.8, 20–51 years) who reported regular men-
struation and who were not taking any hormonal agents.
Participants were handed two sets of questionnaires
and asked to answer them at home and return them by
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mail. One set was to be completed on the day they re-
ceived it, and the other to be completed 2 weeks later.
Since PMS symptoms commonly express in the latter
half of the menstrual cycle, this survey only used data
recorded 2 weeks or more after the beginning of the
cycle. If a participant completed the forms twice in
the luteal phase, only the second set was analyzed. Sub-
jects who failed to return the second set of question-
naires were recalled by e-mail; those who did not
complete both questionnaires were excluded.
Measurements
Each questionnaire contained the Japanese version of
the DRSP, the Center for Epidemiologic Studies Dep-
ression Scale (CES-D),20 the PMDD scale,21 and the
Numerical Rating Scale (NRS) for general health status.
The CES-D is a self-reported 20-item questionnaire
used to detect depression. The score ranges from 0 to
60, with a higher score indicating more severe depres-
sion; scores of >19 are considered borderline to full de-
pression. The Japanese version of this tool was created
in 1985, and has since been established as a valid and
reliable depression scale in many studies.20
The PMDD scale used the Japanese version of the
DSM-5 diagnostic criteria for PMDD. These criteria in-
clude 11 items regarding physical and emotional symp-
toms that emerge 1–2 weeks before menstruation and
disappear after onset of menstruation. Participants an-
swer these questions retrospectively based on recollec-
tion of their symptoms. The remaining three items
ask how the mentioned symptoms interfered with
daily life. All items are ranked from 1 to 4, with higher
scores indicating more severe symptoms. Previous
studies have confirmed the validity and reliability of
the Japanese PMDD scale.21,22
The NRS used in this study was an 11-point scale
used to assess general health status on the day the
scale was completed, from 0 (the worst of your life)
to 10 (the best of your life).
Reliability and validity
To assess the internal consistency of the Japanese ver-
sion of the DRSP, we calculated Cronbach’s a’s for the
total DRSP and for each of its three subscales. Cron-
bach’s a’s of 0.7–0.8 are considered satisfactory.
To confirm criteria validity, we used the CES-D,
PMDD scale, and NRS for general health status. We cal-
culated Pearson’s coefficients, with p values, between the
total score of the 21 symptom-related items in the DRSP
Japanese version and the mentioned three measures. We
also calculated correlations between the depressive symp-
toms subscales in the DRSP and CES-D. Two sided tests
were done with a significance level of 0.001. Statistical an-
alyses were performed using Stata version 15.1.
Ethical considerations. The Kyoto University Ethics
Committee approved this study. The aims and proce-
dures of this study were explained to all participants,
and they were permitted to withdraw from the study
at any time. Written informed consent was obtained
from each participant.
Results
Development of a Japanese version
of the DRSP and cultural adaptation
After obtaining the original DRSP authors’ permission18
to translate the DRSP into Japanese, we first developed
an Item Definition Table that described ‘‘the concepts
being measured along with translation alternatives.’’
The second step involved forward translations of the
DRSP, performed independently by a Japanese doctor
of gynecology and by a professional nurse; in the third
step, yet another Japanese doctor of gynecology joined
the team in their comparison and tentative reconcilia-
tion of these two translations. We then took this tenta-
tive translation to two native English scholars intimately
familiar with Japanese psychology and culture, for their
double-blinded translation back into English.
Next, we convened a team including twomore clinical
psychiatrists to discuss the discrepancies and difficulties
emerging in the back translation based on their clinical
experience with PMS and PMDD patients. In step 7,
>10 native Japanese speakers proofread our Japanese
DRSP and independently affirmed that no revisions
were needed. In step 8, we interviewed eight outpatients
with PMS, including five with PMDD seeing psychia-
trists at Kyoto University Hospital, to evaluate their re-
actions and responses to our Japanese DRSP.
Their median time to complete the DRSP for
1 day’s symptoms was 2 minutes 5 seconds. Three
of the patients had no questions or comments about
the tool; five had opinions or comments, presented
in Table 1. Based on our discussion of these opinions,
we concluded that no linguistic changes were needed.
In step 9, all members of the translation team dis-
cussed the results of the cognitive interviews, and in
step 10, we developed a final version of the Japanese
DRSP. In steps 11 and 12, this Japanese DRSP was
reported to all the stakeholders and was archived.
(Supplementary Appendix Tables SAT2 and SAT3).




Demographic profile of participants. Of 119 partici-
pants, 118 completed questionnaire sets 14 or more
days after the start of menstruation. In 11 cases, the
participants’ two response sets were both in the period
beginning 2 weeks after the onset of menstruation, so
we excluded their earlier response sets, leaving a total
of 107 responses within the period of concern Fig 1.
Respondents’ median age was 30 years (ranging from
21 to 46), and their median date of response was 21
(15–35) days into their menstrual cycle (Table 2). Their
median total score of the 24 items on the Japanese
DRSP was 34 (24–85), with 23 scoring >50 on the Japa-
nese version of DRSP and >19 on the CES-D.
Internal consistency. Cronbach’s a for the total DRSP
score was 0.93 for the luteal phase. The internal consis-
tencies of depression symptoms, physical symptoms,
and anger and irritability were 0.86, 0.68, and 0.80, re-
spectively (Table 3).
Concurrent validity. Patients’ total DRSP during the
late luteal phase significantly correlated with their
CES-D score, PMDD scale score, and NRS score
(Table 4). The CES-D score correlated more strongly
with the summary score of the depressive symptoms
subscale of the DRSP than with the total DRSP score.
Discussion
This is the first documented translation of any medical
questionnaire in Japan following the new TCA guide-
lines of the PRO Consortium. The Japanese DRSP
was developed following all the steps in the PRO Con-
sortium’s translation guide. Following the TCA steps,
we were able to discuss the uniqueness of expressions
Table 1. Summary of Premenstrual Syndrome/Premenstrual
Dysphoric Disorder Patient Cognitive Interviews (n= 8)
Characteristics of participants (median, range)





Symptoms I cannot understand feeling ‘‘on edge’’ because I
do not have that symptom.
It is strange that this questionnaire has no
question on peripheral edema, because I have
that symptom.
It is difficult to distinguish between breast
tenderness and breast swelling.
Instruction Instructions say to answer about ‘‘today,’’ but on
item 15 (had trouble getting to sleep or staying
asleep), I have to answer about last night.
Answering about today is tough because my
symptoms change during the day.
Table 3. Internal Consistency (Cronbach’s a) for Summary
Scores of the Daily Records of Severity of Problems
in Luteal Phase
Item number Chronbach’s a
Total scores Item 1–21 0.93
Depressive symptoms Item 1.2.3.14.15.16 0.86
Physical symptoms Item 18.19.20.21 0.68
Anger/irritability Item 7.8. 0.80
FIG. 1. Number of participants.
*Remove the earlier answer.
CD = cycle date; CES-D =Center for Epidemiologic
Studies Depression Scale; DRSP =daily record of
severity of problems; NRS =Numerical Rating Scale;
PMDD = Premenstrual Dysphoric Disorder.
Table 2. Participants’ Demographic Data
Demographics (median, IQR)
Age 30 (26–36)
Cycle day on the response date 21(17–26)
Total score of Japanese version of the DRSP
(missing value n = 2)
34 (24–85)
Total score of CES-D (missing value n = 2) 9 (5–16)
Total score of PMDD (missing value n = 4) 30 (23–41)
NRS for general health (missing value n = 4) 7 (5–8)
CES-D, Center for Epidemiologic Studies Depression Scale; DRSP, daily
record of severity of problems; NRS, Numerical Rating Scale; PMDD, Pre-
menstrual Dysphoric Disorder.
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that Japanese patients often use in clinical settings, be-
cause our translating team included several clinicians
who treat many PMS/PMDD patients.
Another point of discussion was verb tense. In the
meeting of all the translation members, which included
both native Japanese and English speakers, we found
that in Japanese, current symptoms are more readily
expressed in the present tense than the past tense.
We decided to adopt the past tense following original
English expression, but changed the instruction guide
sentence in the DRSP sheet so that participants would
understand they could record their symptoms at night
while looking back on their whole day. As a result, we
needed no major changes to the Japanese DRSP after
interviewing the PMS/PMDD patients. We had no dif-
ficulty implementing the TCA process using the new
translation guide, but found it quite useful.
We confirmed the reliability and validity of the Jap-
anese version of the DRSP in 119 Japanese women
whose PMS ranged from asymptomatic to severe. The
internal consistency of our Japanese DRSP was quite
high, and the concurrent validity with the CES-D,
PMDD scale, and NRS for general health status was
confirmed. The relatively low Cronbach’s a for the
physical symptoms summary score was considered to
be due to variations in both the cycle dates on which
data were acquired and to the severity of the partici-
pants’ premenstrual symptoms. With regard to concur-
rent validity, the correlation with the CES-D was higher
for the depressive symptoms subscale than for the total
DRSP, indicating that the DRSP does not assess depres-
sion, but more specifically evaluates PMS/PMDD.
Limitations and discussion
Our translation process overcame many limitations
implicit in less rigorous methods. Our use of a 2-
week cutoff to approximate the beginning of the luteal
phase might be disputed, but we did confirm the regu-
larity of menstruation of all our participants in the
recruiting process. On the positive side, our recruit-
ment of participants from a variety of medical facilities
provided a broad range of ages and social backgrounds.
Our statistical confirmations include the selection bias
inherent in using a convenience sample of outpatients,
and some might criticize our sample size of 119. Despite
our relatively small sample size, the fact that we were still
able to derive a high Cronbach’s a as well as highly sig-
nificant correlations with CES-D, PMDD, and NRS
scores confirms both the internal consistency and exter-
nal validity of our Japanese version of the DRSP.
To perfect this analysis, we need to collect Japanese
version of DRSP data with more precise cycle dates
by taking continuous symptoms recording throughout
menstruation cycle. If we can get patients to continu-
ously monitor their daily symptoms, our Japanese ver-
sion of the DRSP should prove a highly reliable scale
for premenstrual symptoms.
In conclusion, our Japanese translation of the DRSP
provides for the first time a measurement tool precisely
comparable with the English original on both linguistic
and statistical grounds. In addition, our Japanese ver-
sion of the DRSP displays baseline psychometric prop-
erties to measure premenstrual symptoms for Japanese
women. Additional studies are expected to confirm its
more adequate reliability and validity.
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Table 4. Correlation of Daily Records of Severity
of Problems Summary Scores with Other
Measures of Severity
PMDD Scale Total CES-D Total NRS
Total 0.57* 0.71* 0.48*
Depressive Symptoms 0.52* 0.74* 0.49*
Physical Symptoms 0.27 0.24 0.23
Anger/Irritability 0.43* 0.41* 0.29
*p < 0.001
PMDD Scale, Premenstrual Dysphoric Disorder Scale; CES-D, Center for
Epidemiologic Studies Depression Scale; NRS, Numerical Rating Scale.
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